Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10940388 | 0.96 | CYP1A2 (0.46) | DGKAHTR2CPRSS1PRSS2PRSS3 | |
| SCHEMBL10938475 | 0.96 | CYP1A2 (0.46) | DGKAHTR2CPRSS1PRSS2PRSS3 | |
| SCHEMBL10941254 | 0.95 | CYP1A2 (0.46) | DGKAHTR2CCYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL10943783 | 0.91 | CYP1A2 (0.47) | DGKAHTR2CCYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL8105421 | 0.88 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL7606203 | 0.88 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL10521274 | 0.88 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL10520894 | 0.88 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL8099497 | 0.88 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| Hexaminolevulinate SCHEMBL1177698 | 0.87 | HTR2C (0.65) | DGKAHTR2CPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221408-A1 | COMPOSITION | EARTH CORPORATION (JP) | 2025-07-10 | — | — | US | disclosed |
| EP-4473837-A1 | COMPOSITION | Earth Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-4147703-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115666593-A | Therapeutic agent for epithelial cancer | 国立大学法人大阪大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220355283-A1 | DRUG, DRUG MANUFACTURING METHOD, AND WATER PURIFICATION METHOD | ACENET INC (JP) | 2022-11-10 | — | — | US | disclosed |
| US-8724296-B2 | Solid electrolytic capacitor and fabrication method thereof | SANYO ELECTRIC CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8425805-B2 | Conductive polymer film, electronic device, and methods of producing the film and the device | SANYO ELECTRIC CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20120049136-A1 | CONDUCTIVE POLYMER FILM, ELECTRIC DEVICES AND METHODS FOR MANUFACTURING THE CONDUCTIVE POLYMER FILM | SANYO ELECTRIC CO., LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20110051319-A1 | CONDUCTING POLYMER MEMBRANE, METHOD OF MANUFACTURING CONDUCTING POLYMER MEMBRANE, AND ELECTRONIC DEVICE | SANYO ELECTRIC CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100271757-A1 | SOLID ELECTROLYTIC CAPACITOR AND FABRICATION METHOD THEREOF | SANYO ELECTRIC CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100232090-A1 | CONDUCTIVE POLYMER FILM, ELECTRONIC DEVICE, AND METHODS OF PRODUCING THE FILM AND THE DEVICE | SANYO ELECTRIC CO., LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-0596524-B1 | Hepatocyte growth factor HGF converting protease and gene encoding said protease | MITSUBISHI CHEM CORP (JP) | 1999-04-21 | — | — | EP | disclosed |
| US-5677164-A | PROTEIN | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5466593-A | DNA fragments and gene expression | MITSUBISHI KASEI CORPORATION (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0596524-A2 | Hepatocyte growth factor HGF converting protease and gene encoding said protease | Mitsubishi Chemical Corporation (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | DGKA 4500/4885HTR2C 4834/4885PRSS1 2610/4885 |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | EPCAM, EGFR, MUC1 | DGKA 2445/4885HTR2C 4809/4885PRSS1 1540/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | DGKA 1932/4885HTR2C 4036/4885PRSS1 4379/4885 |
| US-20250221408-A1 | COMPOSITION | GGPS1, PGGT1B, HBG2 | DGKA 1002/4885HTR2C 3451/4885PRSS1 3844/4885 |
| US-20220355283-A1 | DRUG, DRUG MANUFACTURING METHOD, AND WATER PURIFICATION METHOD | ABCB1, CYP2D6, POR | DGKA 3775/4885HTR2C 2868/4885PRSS1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.